Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome by Tellado, Matías Nicolás et al.
Radiology and Oncology  |  Ljubljana  |  Slovenia  |  www.radioloncol.com
Radiol Oncol 2020; 54(1): 68-78. doi: 10.2478/raon-2020-0014
68
research article
Electrochemotherapy in treatment of 
canine oral malignant melanoma and factors 
influencing treatment outcome
Matías Nicolás Tellado1, Felipe Horacio Maglietti2, Sebastián Diego Michinski3, 
Guillermo Ricardo Marshall3, Emanuela Signori4
1 VetOncologia Cancer Clinic, Ciudad de Buenos Aires, Argentina
2 Instituto Universitario del Hospital Italiano - CONICET, Ciudad de Buenos Aires, Argentina
3  Instituto de Física del Plasma, Departamento de Física, FCEyN, Universidad de Buenos Aires - CONICET, 
Ciudad de Buenos Aires, Argentina
4 CNR-Institute of Translational Pharmacology, Roma, Italy
Radiol Oncol 2020; 54(1): 68-78.
Received 31 December 2019
Accepted 23 February 2020
Correspondence to: Felipe Horacio Maglietti, Instituto Universitario del Hospital Italiano - CONICET, Ciudad de Buenos Aires, C1199ACL, 
Argentina. E-mail: felipemaglietti@gmail.com
Matías Nicolás Tellado and Felipe Horacio Maglietti contributed equally to this work.
Disclosure: No potential conflicts of interest were disclosed.
Background. Oral malignant melanoma is the most common, but aggressive oral cancer in dogs with poor progno-
sis. Electrochemotherapy (ECT) has therapeutic potential in such tumors as effective local treatment. Therefore, the 
aim of this prospective clinical study was to evaluate treatment effectiveness of ECT in as first line treatment for canine 
oral malignant melanoma, and search for factors influencing treatment outcome.
Methods. Sixty-seven canines with primary oral malignant melanoma, non-candidates for first-line therapy, were 
enrolled. All dogs received ECT and follow-up exams for the span of two years.
Results. Based on RECIST criteria, the objective response rate was 100%, 89.5%, 57.7%, and 36.4%, in stage I, II, III and 
IV, respectively. Only patients in stage I, II and III with partial or complete response improved their quality of life. The 
median time to progression was 11, 7, 4 and 4 months, and median survival time after the treatment was 16.5, 9.0, 7.5 
and 4.5 months, for patients in stage I, II, III and IV, respectively. Significantly better was local response in stage I and 
II disease (p = 0.0013), without the bone involvement (p = 0.043)
Conclusions. Electrochemotherapy is effective local treatment of oral canine malignant melanoma when no 
alternative treatment is available. Better response is expected in stage I and II patients with tumors without bone 
involvement. 
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Introduction
Oral malignant melanoma represents 6% of neo-
plasms in canines, being the most common oral 
cancer among that species. It is more aggressive 
and has a poorer prognosis than any other mela-
noma.1,2 The mean age at diagnosis is 11.6 years.3 
Most common breeds affected by mela-
noma are Cocker Spaniel, German Shepherd, 
Pointer, Weimaraner, Golden Retriever, Labrador 
Retriever, Poodle, Chow-Chow and Boxer. It usu-
ally infiltrates locally, with metastatic progression 
in more than 80% of the cases. Typically, there is a 
better outcome and prognosis with early diagnosis 
and/or rostral location. On the other hand, worse 
prognosis is associated with late diagnosis, caudal 
location, presence of satellite lesions, and when 
dysphagia and dyspnea are present.4
It is known that lack of treatment is associated 
with poor survival times (average of 65 days)2, 
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while best survival times are achieved with clean 
margins at surgical excision plus radiotherapy. 
Therefore, the latter is considered the first-line 
treatment for this neoplasm, with a recurrence of 
distant metastasis that can arise 4 to 8 months after 
the end of it. Given the fact that most of the tumors 
in advanced stages are already involving bony 
structures, complete surgical resection is often 
very aggressive and has poor prognosis. Adjuvant 
chemotherapy does not increase response rates or 
adds any survival benefit to the patients.5,6
Electrochemotherapy (ECT) is a therapeutic mo-
dality that has been gaining ground in Oncology 
since the Standard Operating Procedures were 
published in 2006.7 ECT consists in the application 
of an electric field to a tumor in order to increase 
the uptake of bleomycin that was previously ad-
ministered (locally or intravenously) at a very low 
dose8,9; alternatively, cisplatin can be used locally 
with equally good results.10 ECT is primarily indi-
cated for cutaneous and subcutaneous tumors of 
any histology. After the electric field is applied, a 
cell membrane permeabilization is produced by a 
physical phenomenon known as electroporation, 
affecting all tumor cells, regardless of the histologi-
cal tissue.11 A meta-analysis of ECT clinical stud-
ies in human oncology showed that the overall 
objective response (OR) rate varies from 62.6% to 
82.2% depending also on which route was used to 
administer the drug.12 Great efforts are being made 
to extend ECT to non-cutaneous locations such as 
liver13, brain14, and bones.15 Moreover, an endo-
scopic electrode was developed for treating the 
colon.16 The considerable experience and deeper 
understanding gained since ECT inception, lead to 
the publication of new and more flexible Standard 
Operating Procedures.17 In veterinary medicine, 
ECT is a well-established therapy with multiple 
indications and proven efficacy.18,19 It has been 
reported very good results for treating mast-cell 
tumors (OR 62.3-100%)20–22, sarcomas (OR 90%)23, 
perianal tumors (OR 94%)24, nasal duct tumors (OR 
91%)24,25, among others, with minimum to absent 
side effects.
In vivo, ECT is remarkably more effective in 
immunocompetent subjects.26 Different mecha-
nisms for the induced local immune response have 
been demonstrated in preclinical studies. Some of 
them have also been observed in human patients. 
However, this local immune response does not in-
duce an abscopal effect, and intense efforts are be-
ing made in order to achieve it.27,28
The clinical experience with melanoma immu-
notherapies seems promising, with increasing evi-
dence that combined approaches may be required 
to ensure durable responses in the majority of the 
patients.29
In this prospective clinical study, we present re-
sults obtained from 67 canine patients affected by 
oral malignant melanomas that were treated with 
ECT and later followed-up for up to two years. We 
also discuss ECT benefits in comparison to classic 
therapeutic approaches and search for factors in-
fluencing treatment outcome.
Methods
In this longitudinal prospective study, sixty-seven 
(67) canine (Canis familiaris) patients with oral ma-
lignant melanoma and not candidates for first-line 
therapy were enrolled. Primary goals consisted on 
evaluating local response and survival times. In 
addition, we also decided to evaluate quality of 
life, time to progression and disease-free survival 
times. Treatments were performed from 10/2014 
through 12/2017 at Centro de Especialidades 
Medico Veterinarias, Buenos Aires, Argentina.
Inclusion criteria:
 ‒ Patients with oral malignant melanoma at 
any stage.
 ‒ Patients able to stand general anesthesia.
Exclusion criteria:
 ‒ Pregnant females
 ‒ Patients are candidates for surgery and 
owner agrees to perform treatment.
 
Patient evaluation
Participants’ diagnosis was confirmed by histopa-
thology (surgical biopsies). Immunohistochemistry 
was performed in selected cases for amelanotic 
melanoma or when diagnosis was not definitive.
Patients were staged according to the WHO stag-
ing system for canine oral melanoma (Table 1).30 
They underwent a complete physical examination, 
complete blood count (CBC), and serum biochemi-
TABLE 1. WHO criteria for staging canine oral melanoma
Stage Tumor diameter Lymph node involvement Metastasis
I < 2 cm No No
II 2 - 4 cm No No
III > or = 4 cm No No
 Any Yes No
IV Any Yes or No Yes
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cal analysis. The size of the tumor was measured 
using a caliper or by CT scan for masses involving 
deeper structures such as retro-orbital region, na-
sopharynx or nasal cavity. In addition, to confirm 
or rule out bone involvement when plain radio-
graphs were not fully diagnostics.
Evaluation for metastatic disease was performed 
via 3-view thoracic radiographs, abdominal ultra-
sound and fine-needle aspirate of regional lymph 
nodes. CT scan was performed when radiographs 
were not diagnostics. Data gathered in all patients 
included: age, weight, sex, breed, stage at time of 
diagnosis, histologic subtype, presence or not of 
bone infiltration, location of the tumor within the 
mouth (was considered caudal when compromis-
ing the caudal third of the hard palate, soft palate, 
oropharynx, angle of the mandible, ramus of the 
mandible or the tonsillar region. Otherwise, it was 
considered to be rostral), local response, quality 
of life, presence/absence of metastasis, number of 
ECT sessions, new metastasis after treatment, time 
to progression, disease-free survival times (when 
CR was obtained), overall survival times and cause 
of death.
ECT procedure
ECT and surgical resection of enlarged regional 
lymph nodes were performed under general anes-
thesia.
Chosen anesthesia protocol was proved to pro-
vide adequate comfort throughout the procedure, 
and consisted on premedication with IM (intramus-
cular) administration of xylazine (Xylazine 100®, 
Richmond, Buenos Aires, Argentina) 0.5 mg/kg and 
tramadol (Tramadol®, John Martin, Buenos Aires, 
Argentina) 2 mg/kg. Induction was performed 
with IV (intravenous) administration of propo-
fol (Propofol Gemepe®, Gemepe, Buenos Aires, 
Argentina) 2-3 mg/kg. For maintenance, isoflurane 
(Zuflax®, Richmond, Buenos Aires, Argentina) 
2–3% and intravenous fentanyl (Fentanyl 
Gemepe®, Gemepe, Buenos Aires, Argentina) 2 
mcg/kg were used. Amoxicillin with clavulanic 
acid (Clavamox® Zoetis, Buenos Aires Argentina) 
15 mg/kg/bid and meloxicam (Meloxivet®, John 
Martin, Buenos Aires, Argentina) 0.2 mg/kg/SID 
were administered orally for prophylaxis and an-
algesia after the treatment according to the needs 
of each patient.
ECT was initiated by using IV (intravenous) 
bleomycin (Blocamicina®, Gador, Buenos Aires, 
Argentina) at a dose of 15 000 IU/m2 of body sur-
face. Eight minutes later, in order to allow drug 
distribution, electric pulses were delivered (fol-
lowing Standard Operating Procedures)17 with a 
BTX ECM 830 (Harvard Apparatus, Holliston, MA, 
USA) unit. Each train of pulses consisted of eight (8) 
square wave monopolar pulses of 400V (1000V/cm) 
100 μs long at 10 Hz. The number of trains applied 
varied according to the tumor size, aiming to cover 
the whole tumor volume plus safety margins be-
yond it. In all cases, a 6-needle electrode was used 
(Figure 1A.), but for nasal duct invasion, the Single 
Needle Electrode® was indicated (Figure 1B.).25 
This electrode uses the same pulse parameters, 
but thirty-two (32) instead of eight (8) pulses are 
delivered on each train. Recommendations to re-
port results in electrochemotherapy studies from 
Campana et al. were followed.31
Patient follow-up
Patients were scheduled for checkups at 14, 30 
and 60 days after treatment. If no further sessions 
were needed, follow-ups were required every 3 to 
4 months until the end of the study. On each visit, 
a complete clinical examination and thoracic radio-
graphs were performed to determine if lymph node 
enlargement and/or development of lung metasta-
sis respectively were noticed; as they represent the 
most common sites for metastatic dissemination.6
 
Treatment response evaluation
According to the RECIST criteria, the response was 
determined at 30 days and confirmed at 60 days 
FIGURE 1. Electrodes used to treat patients. In (A) a render of the six-needle 
electrode used. It consists of two rows of needles separated 4 mm from each other. 
In (B) a picture of the Single Needle Electrode for nasal duct treatment.
A B
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Likewise, if the achieved response was a progres-
sive disease (PD), a new session was performed. 
Any enlarged regional lymph node noticed by the 
time of a follow-up (with metastatic spread deter-
mined by fine needle aspirate) was surgically re-
moved (Figure 2).
Statistical analysis
Statistics were performed using MedCalc® ver-
sion 19.1. Fisher exact test was used to determine 
the significant association between local response 
and different factors studied. Multivariate logistic 
regression analysis was performed with the factors 
that showed significant association with local re-
sponse.
Kaplan-Meier curves were calculated, and their 
significance determined by the log-rank test, for 
different factors affecting survivorship and time 
to progression. Cox multiple regression analysis 
using forward regression method was performed 
with statistically significant factors for survival.
 
Ethics approval and consent to 
participate
All regulations from the Consejo Profesional de 
Médicos Veterinarios were followed. Informed 
consents were signed by the owners. This work 
was approved by the IACUC of the School of 
Veterinary Sciences, University of Buenos Aires, 
Argentina. Protocol number: 2018/31.
FIGURE 2. Treatment plan algorithm.
CR = complete response; ECT = electrochemotherapy; PD = progressive 
disease; PR = partial response; SD = stable disease
after treatment. Survival time was determined as 
of time in between first ECT treatment and either 
end of the study or death of the patient. Time to 
progression was determined to be from the day 
of the ECT session that achieved a confirmed re-
sponse through the day of an either local or distant 
relapse. Disease-free survival time was calculated 
only among patients that were able to achieve a 
CR. It was determined as time between a CR was 
achieved through the day where a relapse, local or 
distant, was evidenced.
Quality of life
The quality of life was assessed before the first 
ECT treatment and by each follow up exam us-
ing a questionnaire inspired in the observations of 
Lynch et al.32 It was filled by the owner (provided 
in additional material). It consisted of three (3) clin-
ical and behavioral questions, with values between 
0 and 3. Final score was obtained by the sum of all 
questions, with lower scores representing better 
results (score of 0) and higher scores worse quality 
of life (score of 9). In order to consider if quality of 
life was either improved or worsened, a difference 
of at least two (2) units was required when com-
paring both scores (day of the treatment vs. each 
follow-up).
Data obtained by the treating oncologist was 
also included in the patient’s medical record.
Criteria for ECT retreatment and 
additional therapy
If tumor growth was detected in any given fol-
low-up visit, then a new session was scheduled. 
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Results
Demographics of the treated patients is in Table 2. 
The patients were followed up for two years. Two 
(2) out of the sixty-seven (67) treated patients re-
mained alive by the end of the study. Sixty-one 
percent of the patients (41) required a single ses-
sion to achieve a final response, 30% (20) required 
two, 7% (5) required three and 1% (1) required four 
procedures. Time between sessions varied in each 
case depending on tumoral regrowth, and usually 
is between one and two months.
Local response
After a median of 1.5 treatment sessions (regard-
less of the stage), the overall objective response 
(OR) rate was 70.1% (47); with 20.9% (14) com-
plete responses (CR), 49.3% (33) partial responses 
(PR), 16.4% (11) stable diseases (SD) and 13.4% (9) 
progressive diseases (PD). Local response in each 
stage is presented in Figure 3.
Logistic regression analysis showed that early 
stages of disease (stages I and II) were associated 
with significantly higher objective response rates 
than late stages (III and IV), 93.3% vs. 51.4%, re-
spectively (HR: 0.08, 95% CI: 0.02–0.36, p = 0.0013) 
(Table 3).
Time to progression and disease-free 
survival times
The median time to progression was 11 (range 
4–30) months, 7 (range 3–21) months, 4 (range 2–4) 
months and 4 (range 1–4) months, for stages I, II, III 
and IV, respectively. 
FIGURE 3. The bars show the sum of partial and complete 
response percentages obtained on each stage. For stage 
I: complete responses (CR) 72.7% (8) partial responses (PR) 
27.3% (3) stable diseases (SD) 0% progressive diseases (PD) 0%, 
stage II: CR 21.1%(4) PR 68.4% (13) SD 0% PD 10.5% (2), stage III: 
CR 7.7% (2) PR 50% (13) SD 26.9% (7) PD 15.4% (4) and stage IV: 
CR 0% PR 36.4% (4) SD 36.4% (4) PD 27.3% (3).
TABLE 2. Patients’ demographics
Characteristics of 67 patients Mean (range) (%)
Age (years) 11.7 (6–16)
Sex ratio (M:F) 37:30
Body weight (kg) 22.6 (3.5–58)
Breeds  
   Crossbreed 24 (35.8%)
   Labrador retriever 9 (13.4%)
   Cocker spaniel 7 (10.4%)
   Golden retriever 6 (8.9%)
   Beagle 4 (5.9%)
   Poodle 4 (5.9%)
   Rottweiler 3 (4.4%)
   Doberman 2 (2.9%)
   Shar-Pei 2 (2.9%)
   Dogo 1 (1.4%)
   English Mastiff 1 (1.4%)
   Chow-Chow 1 (1.4%)
   Basset Hound 1 (1.4%)
   Pekingese 1 (1.4%)
   Dalmatian 1 (1.4%)
Location (Rostral : Caudal) 36 : 31
Stage  
   I 11 (16.5%)
   II 19 (28.3%)
   III 26 (38.8%)
   IV 11 (16.4%)
Histologic subtype  
   Epithelioid 17 (25.4%)
   Mixed 17 (25.4%)
   Spindle cell 17 (25.4%)
   Anaplastic 9 (13.4%)
   Others 7 (10.4%)
The multivariate analysis for the time to pro-
gression showed that stages I (p = 0.0005) and 
II (p = 0.0094), and absence of bone invasion 
(p = 0.043) were predictive factors for longer times 
to progression (Table 4).
Considering the patients who achieved a com-
plete response (n = 14), the median disease-free 
survival time for these patients was 12.5 (range 
3–30) months. Among them: 2 (14%) remained 
alive at the end of the study, 6 (43%) died of unre-
lated causes. Only one (7%) developed distant me-
tastases during the follow-up, three months after 
the complete response was obtained. Twelve (86%) 
were treated with only one session of ECT. Four 
(29%) had bone involvement.
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Overall survival time
Median survival time after the treatment was 16.5 
(range 4–30) months, 9 (range 4–21) months, 7.5 
(range 3–17) months and 4.5 (range 2–7) months, 
in stage I, II, III and IV, respectively. Two patients 
remained alive at the end of the study, therefore, 
in the statistical analysis were censored (Figure 4).
In multivariate analysis for survival time, stage 
IV (p = 0.0001) was a negative predictive factor. On 
the contrary, stage I (p = 0.0083) and the absence of 
bone involvement (p = 0.0340) were predictive fac-
tors for longer survival (Table 4).
 
Cause of death
Euthanasia was the main cause of death during the 
course of this study, representing 77.6% (52) of the 
deceased patients, where 49.3% (33) of those eu-
thanasias were performed due to local progression 
and 28.4% (19) due to metastatic progression of the 
disease. Unrelated causes of death reached 17.9% 
(12) and finally, 3% (2) of the overall enrolled pa-
tients remained alive by the end of the follow-up 
period (24 months).
Metastasis
Among patients with no metastatic lesions at the 
time of diagnosis, 23.9% (16) developed new metas-
tasis during subsequent follow-up visits. Patients 
treated in stage I did not develop new metastasis. 
For stages II, III and IV, the number of patients that 
developed metastasis after the first visit was also 
similar, being 31.6%, 36.8% and 31.6%, respective-
ly.
Quality of life
Patients in stage I with the tumor in rostral location 
had no negative impact on their quality of life be-
fore or after the treatment. Patients in stages I (with 
FIGURE 4. (A) Time to progression curve (Cox proportional-hazards regression, n = 67, p < 0.0001). (B) Overall survival time (Cox 
proportional-hazards regression, n = 67, p < 0.0001). (C) Survival time by stage (Kaplan-Meier curves of survival, n = 67, p < 0.0001). 
(D) Disease-free survival time (Kaplan-Meier, n = 14). 
A B
C D
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the tumor in a caudal location), II and III presented 
the following signs and symptoms: bleeding, acci-
dental biting of the tumor, pain and impossibility 
to eat adequately. Among the latter, those who ob-
tained a CR or PR after ECT, had an improvement 
in their quality of life (Figure 5). On the contrary, 
patients that obtained a SD or PD, did not. Patients 
in stage IV did not improve their quality of life re-
gardless of the obtained response.
Discussion
ECT is a very effective local treatment for tumors 
originating almost any histological type of tissue. 
In the last few years, the treatment has become 
readily available in many countries due to its mul-
tiple advantages. Among them: high efficacy, low 
cost and simplicity at time of performing. The 
aforementioned, combined with the availability of 
inexpensive devices, made possible its expansion 
through Latin America, where radiotherapy con-
tinuous to be a non-affordable therapeutic alterna-
tive. Since often ECT is the only available option, 
professionals tend to treat indiscriminately, with-
out even taking in consideration if that particu-
lar patient is indeed a surgical candidate or not. 
Therefore, we believe that veterinarians should 
assess more carefully, in advance, if good results 
could potentially be achieved with this modality, 
in order to consider or plan a therapeutic alterna-
tive. We think that for an adequate determination 
who might be considered a good candidate for the 
treatment, further studies are needed, with the 
hope that one day ECT could become a first-line 
therapy for many tumors.
In this study, frequency of breeds, differences in 
gender predisposition and age at the time of diag-
nosis were in accordance with different authors.33,34 
Also, melanomas located in the tongue were rare, 
as reported by others.35 The largest group of pa-
tients enrolled in the study were staged II or III. 
This is probably related to the fact that owners 
were not able to recognize the characteristic lesions 
earlier in the onset of the disease, due to the intra 
oral location of the tumor. Early signs and symp-
toms were probably unnoticed by the caretakers, 
but more prominent symptomatology caused by a 
more advanced stages of the disease was the red 
flag that made owner seek for medical advice.36 We 
had a similar prevalence of histological subtypes to 
the one reported by Ramos-Vara et al., except for a 
lower incidence of spindle cell type. Also, we had a 
higher incidence of amelanotic melanomas.33
Best local responses were obtained in patients 
with tumors smaller than 4 cm in diameter (stages 
I and II). We came to the conclusion that smaller tu-
mors are easier to treat with ECT than larger ones, 
not only due to the limitation related to the size of 
the electrode (lower chances to reach larger tumor 
extensions), but also because bigger tumors have 
necrotic areas, and a very inhomogeneous vascu-
larization, affecting the distribution of the drug. 
We addressed this particular issue in a previous 
TABLE 3. Univariate (Fisher exact test) and multivariate (Logistic regression analysis) test for analyzing the association between OR and different factors




OR 95% CI Logistic Regression Analysis p
Sex (M/F) 37/30 p = 0.602 – –
Location (Rostral/Caudal) 36/31 p = 0.062 – –
Bone Involvement (Yes/No) 43/24 p = 0.026 automatically excluded –
Metastasis present, excluding lymph nodes (Yes/No) 10/57 p = 0.150 – –
Early-stage (stages I+II/stages III+IV) 30/37 p = 0.00016 0.08(0.02-0.36) 0.0013
FIGURE 5. (A) Stage II patient with melanoma in the soft palate, before the 
treatment. (B) Final response obtained 30 days after third round of ECT. Completely 
absent tumoral tissue and a fistula can be seen. Quality of life of the patient 
improved in spite of the fistula, which was asymptomatic.
A B
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TABLE 4. Univariable (Kaplan-Meier) and multivariable (Cox proportional-hazards) analysis of patient-related factors for time to progression and overall 
survival time. Hazard Ratio and 95% Confidence interval is reported
 N. of patients
Overall Survival
[Univariable] P [Multivariable] P
TTP
[Univariable] P [Multivariable] P
Sex          
Male 35 1.58 (0.95–2.63) 0.0634 – – 1.67 (0.99–2.75) 0.0433 – –
Female 30   – –   – –
Location          
Rostral 34 0.71 (0.43–1.16) 0.1596 – – 0.77 (0.47–1.26) 0.2921 – –
Caudal 31   – –   – –
Metastasis          
No (or lynph 
node only) 55 0.29 (0.09–0.88) 0.0001 – – 0.34 (0.12–0.96) 0.0009 – –
Yes 10   – –   – –
Bone Involvement          
Yes 42 2.45 (1.50–4.00) 0.0004       
No 23   (0.24–0.88) 0.0184 0.42 (0.26–0.68) 0.0005 (0.28–0.98) 0.043
Histology          
Epithelioid vs. 
Fusocellular 16 / 16 0.59 (0.31–1.14) 0.1768 – – 0.60 (0.32–1.14) 0.0534 – –
Epithelioid vs. 
Mixed 16 / 17 0.54 (0.28–1.05)  – – 0.49 (0.25–0.96)  – –
Epithelioid vs. 
Anaplastic 16 / 9 0.46 (0.19–1.11)  – – 0.35 (0.14–0.93)  – –
Fusocellular vs. 
Mixed 16 / 17 0.92 (0.44–1.93)  – – 0.82 (0.39–1.72)  – –
Fusocellular vs. 
Anaplastic 16 / 9 0.77 (0.30–1.99)  – – 0.59 (0.22–1.64)  – –
Mixed vs. 
Anaplastic 17 / 9 0.84 (0.33–2.18)  – – 0.73 (0.26–2.04)  – –
Stage          
I vs. II 10 / 18 1.86 (1.03–3.34) <0.0001 Stage I:(0.13–0.74) 0.0083 0.53 (0.30–0.96) 0.0001
Stage I:
(0.07–0.47) 0.0005
I vs. III 10 / 26 3.28 (1.76–6.09)    0.28 (0.15–0.53)  Stage II:(0.24–0.82) 0.0094
I vs. IV 10 / 11 9.05 (2.58–31.75)    0.19 (0.07–0.51)    
II vs. III 18 / 26 0.57 (0.30–1.06)    0.52 (0.27–0.99)    
II vs. IV 18 / 11 0.21 (0.06–0.72)  Stage IV:(2.04–9.29) 0.0001 0.35 (0.13–0.96)    
III vs IV 26 / 11 0.36 (0.10–1.29)    0.67 (0.24–1.90)    
study, by using a combined administration of bleo-
mycin, systemically and locally.37
There is still no consensus on when is the best 
time to perform a second (or subsequent) ECT ses-
sion. In this work, we considered tumor growth as 
the main variable to be taken in consideration for 
that matter. This is based on our 10+ years of ex-
perience performing ECT, and by the fact that we 
were able to identify four different types of out-
comes or evolutions after the first session. In the 
first one, the most common, the tumor gets steadily 
smaller until reaching a stable size or disappearing 
completely. In the second type, the so called “two-
times response”, the lesion reduces its size up to 
one point where it stops for some time, resuming 
shrinkage later until reaching a stable size or dis-
appearing. In the third type, the “apparent unre-
sponsive”, it never gets smaller, stays apparently 
unresponsive to the treatment, but it does not grow 
and can also remain in that steady state for years. 
And finally, in the fourth type, “the insufficiently 
treated”, after an initial short period of shrinkage, 
the tumor starts growing back again. It is known 
that all these types of evolutions are related to the 
bleomycin’s mechanism of action, which consists 
in cutting the DNA strands and inducing mitotic 
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cell death. If the tumor cell are treated while divid-
ing, it will die. However, if there is a number of 
quiescent cells not attempting to enter into cell cy-
cle, they will remain alive. This is the reason why 
this treatment displays selectivity towards divid-
ing cells.9 In the light of the above explained, we 
consider that the only situation that potentially 
opens the door for a subsequent treatment after the 
original one is when a regrowth from a previously 
treated lesion is observed. Otherwise, we can be 
facing a type two or three evolution.
Absence of bone involvement was associated 
with longer times to progression and survival. This 
fact could be attributed partially to how difficult is 
to insert the electrode inside the bone tissue. Even 
when the electrode is properly positioned, changes 
in electric field distribution between bone and tu-
mor tissue can lead to inhomogeneities that will 
lead to inadequate treatment.38 This is in accord-
ance with other authors who treated oral malignant 
melanoma with surgery plus radiotherapy. They 
had better results treating small tumors without 
bone involvement, but they also found that rostral 
location was associated with better responses.39-41 
In this work, location of the tumor did not achieve 
statistical significance to be associated either with 
local response, time to progression or survival.
If we compare frequency of use between ECT 
and other treatment modalities, we find that sur-
gery is the most common one performed. The me-
dian survival time for dogs with malignant mela-
noma treated with surgery alone varies from 5 to 
11 months.42,43 Conservative surgery is only recom-
mended followed by radiotherapy in non-resecta-
ble tumors for local control of the disease. Median 
survival times are similar to the times obtained in 
this work, and that was expected, since both are lo-
cal treatments. When surgery is possible and the 
owner accepts it, we recommend to follow that 
path, as surgery is a well-established technique in 
our setting. In these cases, ECT could be used in 
combination with surgery to extend surgical mar-
gins, or even to treat the scar and reduce the recur-
rence rate (further research is needed to confirm 
this hypothesis). Recurrence rate after incomplete 
surgical resection is high (62–65% vs. 15–22% re-
currence rate with incomplete and complete resec-
tion, respectively), and in those cases we choose to 
perform ECT as a first-line treatment.44
Radiation therapy alone is effective to obtain 
good local control of the disease, especially with 
patients that are not suitable for complete surgical 
excision (the addition of chemotherapy provides 
no additional benefit).39 The response rates are 
similar regardless of the protocol that was used. 
Proux et al. achieved 51% CR, 31% PR, 16% SD and 
1% PD. If we compare these results with the ones 
obtained in this work, we find similar OR rates, but 
with more CR when treating with radiotherapy. 
However, they report a 51% incidence of new me-
tastasis, while in this work, the incidence of new 
metastasis was 28.4%. Results of median overall 
survival time with radiotherapy were 7 months (6–
9 months), also similar to the ones obtained in this 
work, 7.5 months (2–30 months).39 An adequately 
designed clinical study should be designed per-
formed to compare both treatment modalities.
It is well known that melanoma is an extremely 
chemotherapy-resistant tumor, and recent studies 
have been supporting the idea that chemotherapy 
brings little to no benefits based on the analysis of 
results obtained after using the aforementioned 
therapeutic modality. Boria et al.45 reported a tu-
mor remission of 18% in melanoma patients and a 
median survival time of 4 months.
In relation to lymph node involvement, fine-
needle aspiration (FNA) technique is mandatory 
for patient staging.34 Several (FNA) samples ob-
tained from the patients, ended up being positive 
even after unremarkable lymphadenopathy no-
ticed to palpation at the moment of the exam.
Among the limitations we had to face through-
out the making of this study, lack of chances to per-
form immunohistochemistry in every patient, was 
probably, one of the most important. Consequently, 
we had to draw upon the aforementioned tech-
nique only when diagnosis of melanoma was not 
definitive by using simple hematoxylin-eosin stain. 
Another limitation was imaging. As default, bone 
involvement was assessed by plain radiographs. 
CT scan was only performed in selected patients, 
either due to financial constraints or at times when 
we felt X-rays were not giving enough information 
in order to get to a definitive diagnosis.
New immunological approaches are now avail-
able in order to improve the results of local ther-
apy. Promising results have been published by 
Mozillo et al. combining ECT with ipilimumab. The 
ECT session was performed for local control of the 
disease after treatment with ipilimumab. It seems 
that ECT triggered a systemic response, which was 
obtained in 60% of the patients.46
In the last decade, DNA-based immunotherapy 
reached important goals in the treatment of infec-
tious diseases and cancer.47 In a previous study, 
we explored the use of ECT in combination with 
canine IL-2+IL-12 plasmid vector delivered by elec-
troporation, obtaining local control of the disease 
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in patients with different histological neoplasms. 
We observed fever, swelling, and lethargy due to 
the transfection, which had to be treated with cor-
ticosteroids. A single systemic response in lung 
metastasis was obtained48 but further research is 
needed to study this combination.
Milevoj et al. obtained a 67% CR rate in 9 canine 
patients with an oral malignant melanoma treated 
with surgery plus electrochemotherapy plus gene 
electrotransfer with IL-12. They report a declining 
in regulatory T cells number that is associated with 
the treatment.49 Cemazar et al. combined ECT with 
human IL-12 plasmid vector delivered by elec-
troporation and obtained a 72% CR rate in sponta-
neous canine mast cell tumors without side effects. 
They also observed that the therapy prevented lo-
cal recurrences and distant metastasis.50
ECT is a very appealing treatment modality for 
combination with immunotherapies, especially 
with those based on gene electrotransfection. This 
latter technology allows performing the immuno-
therapy at a fraction of the cost when compared 
with traditional immunotherapies. In this sense, 
low income countries may be the most benefited 
from the combination of ECT and gene electro-
transfer.
In conclusion, ECT is an adequate local treat-
ment modality for canine patients with oral malig-
nant melanoma with lesions of up to 4 cm in diam-
eter, i.e. stages I and II, and without bone invasion.
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